Market closed
KemPharm/$ZVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About KemPharm
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Ticker
$ZVRA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
59
Website
KemPharm Metrics
BasicAdvanced
$390M
-
-$2.28
1.98
-
Price and volume
Market cap
$390M
Beta
1.98
52-week high
$9.40
52-week low
$4.20
Average daily volume
490K
Financial strength
Current ratio
2.525
Quick ratio
2.349
Long term debt to equity
150.95
Total debt to equity
152.009
Interest coverage (TTM)
-11.84%
Management effectiveness
Return on assets (TTM)
-31.03%
Return on equity (TTM)
-207.84%
Valuation
Price to revenue (TTM)
14.103
Price to book
9.74
Price to tangible book (TTM)
-11.36
Price to free cash flow (TTM)
-4.78
Growth
Revenue change (TTM)
-14.02%
Earnings per share change (TTM)
75.63%
3-year revenue growth (CAGR)
-6.24%
3-year earnings per share growth (CAGR)
2.59%
What the Analysts think about KemPharm
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for KemPharm stock.
KemPharm Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KemPharm Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KemPharm News
AllArticlesVideos
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
GlobeNewsWire·2 weeks ago
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
GlobeNewsWire·3 weeks ago
Zevra Therapeutics Files Preliminary Proxy
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for KemPharm stock?
KemPharm (ZVRA) has a market cap of $390M as of April 30, 2025.
What is the P/E ratio for KemPharm stock?
The price to earnings (P/E) ratio for KemPharm (ZVRA) stock is 0 as of April 30, 2025.
Does KemPharm stock pay dividends?
No, KemPharm (ZVRA) stock does not pay dividends to its shareholders as of April 30, 2025.
When is the next KemPharm dividend payment date?
KemPharm (ZVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for KemPharm?
KemPharm (ZVRA) has a beta rating of 1.98. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.